Logo image of CS

Credit Suisse Group (CS) Stock Fundamental Analysis

NYSE:CS - New York Stock Exchange, Inc. - US2254011081 - ADR - Currency: USD

0.8858  +0.01 (+0.99%)

After market: 0.899 +0.01 (+1.49%)

Fundamental Rating

1

Taking everything into account, CS scores 1 out of 10 in our fundamental rating. CS was compared to 225 industry peers in the Capital Markets industry. Both the profitability and financial health of CS have multiple concerns. CS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

CS had negative earnings in the past year.
In multiple years CS reported negative net income over the last 5 years.
In multiple years CS reported negative operating cash flow during the last 5 years.
CS Yearly Net Income VS EBIT VS OCF VS FCFCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10B -10B 20B 30B

1.2 Ratios

With a Return On Assets value of 1.00%, CS perfoms like the industry average, outperforming 48.02% of the companies in the same industry.
With a decent Return On Equity value of 10.01%, CS is doing good in the industry, outperforming 69.31% of the companies in the same industry.
Industry RankSector Rank
ROA 1%
ROE 10.01%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CS Yearly ROA, ROE, ROICCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5 -5 -10 -15

1.3 Margins

Looking at the Profit Margin, with a value of 18.68%, CS is in the better half of the industry, outperforming 64.85% of the companies in the same industry.
CS does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 18.68%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CS Yearly Profit, Operating, Gross MarginsCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -20 -40

0

2. Health

2.1 Basic Checks

The number of shares outstanding for CS has been increased compared to 1 year ago.
CS has a worse debt/assets ratio than last year.
CS Yearly Shares OutstandingCS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B
CS Yearly Total Debt VS Total AssetsCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200B 400B 600B 800B

2.2 Solvency

CS has a Debt/Equity ratio of 2.80. This is a high value indicating a heavy dependency on external financing.
CS has a worse Debt to Equity ratio (2.80) than 84.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CS Yearly LT Debt VS Equity VS FCFCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50B 100B 150B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CS Yearly Current Assets VS Current LiabilitesCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50B 100B 150B

3

3. Growth

3.1 Past

The earnings per share for CS have decreased strongly by -702.95% in the last year.
The Revenue has grown by 48.34% in the past year. This is a very strong growth!
The Revenue has been decreasing by -6.52% on average over the past years.
EPS 1Y (TTM)-702.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-576.1%
Revenue 1Y (TTM)48.34%
Revenue growth 3Y-12.77%
Revenue growth 5Y-6.52%
Sales Q2Q%318.56%

3.2 Future

Based on estimates for the next years, CS will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.46% on average per year.
CS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.57% yearly.
EPS Next Y82.2%
EPS Next 2Y39.87%
EPS Next 3Y27.69%
EPS Next 5Y16.46%
Revenue Next Year-4.81%
Revenue Next 2Y-0.32%
Revenue Next 3Y0.61%
Revenue Next 5Y2.57%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CS Yearly Revenue VS EstimatesCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B 25B
CS Yearly EPS VS EstimatesCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CS Price Earnings VS Forward Price EarningsCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CS Per share dataCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

CS's earnings are expected to grow with 27.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y27.69%

0

5. Dividend

5.1 Amount

No dividends for CS!.
Industry RankSector Rank
Dividend Yield N/A

Credit Suisse Group

NYSE:CS (6/9/2023, 8:04:01 PM)

After market: 0.899 +0.01 (+1.49%)

0.8858

+0.01 (+0.99%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-24 2023-04-24/dmh
Earnings (Next)07-27 2023-07-27/bmo
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.50B
Analysts46.09
Price Target1.51 (70.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-126.63%
Min EPS beat(2)-230.24%
Max EPS beat(2)-23.02%
EPS beat(4)0
Avg EPS beat(4)-3226.79%
Min EPS beat(4)-11871.5%
Max EPS beat(4)-23.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)174.77%
Min Revenue beat(2)-4.76%
Max Revenue beat(2)354.29%
Revenue beat(4)1
Avg Revenue beat(4)84.46%
Min Revenue beat(4)-9.84%
Max Revenue beat(4)354.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.18%
PT rev (3m)-56.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-45.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.24
BVpS15.38
TBVpS14.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1%
ROE 10.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 18.68%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)72.35%
Cap/Depr(5y)87.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-702.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-576.1%
EPS Next Y82.2%
EPS Next 2Y39.87%
EPS Next 3Y27.69%
EPS Next 5Y16.46%
Revenue 1Y (TTM)48.34%
Revenue growth 3Y-12.77%
Revenue growth 5Y-6.52%
Sales Q2Q%318.56%
Revenue Next Year-4.81%
Revenue Next 2Y-0.32%
Revenue Next 3Y0.61%
Revenue Next 5Y2.57%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.83%
EBIT Next 3Y24.95%
EBIT Next 5YN/A
FCF growth 1Y-65.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.59%
OCF growth 3YN/A
OCF growth 5YN/A